Renaissance Group LLC reduced its stake in Zoetis Inc. (NYSE:ZTS – Get Rating) by 5.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 159,802 shares of the company’s stock after selling 8,868 shares during the period. Zoetis accounts for about 1.6% of Renaissance Group LLC’s holdings, making the stock its 7th biggest position. Renaissance Group LLC’s holdings in Zoetis were worth $38,996,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently made changes to their positions in the company. Geode Capital Management LLC grew its position in shares of Zoetis by 2.9% during the third quarter. Geode Capital Management LLC now owns 8,550,968 shares of the company’s stock worth $1,655,866,000 after acquiring an additional 238,461 shares during the last quarter. Morgan Stanley grew its position in shares of Zoetis by 4.6% during the second quarter. Morgan Stanley now owns 7,561,487 shares of the company’s stock worth $1,409,158,000 after acquiring an additional 333,952 shares during the last quarter. Massachusetts Financial Services Co. MA grew its position in shares of Zoetis by 0.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 5,360,660 shares of the company’s stock worth $1,308,162,000 after acquiring an additional 24,432 shares during the last quarter. UBS Asset Management Americas Inc. grew its position in shares of Zoetis by 28.3% during the third quarter. UBS Asset Management Americas Inc. now owns 5,261,396 shares of the company’s stock worth $1,021,447,000 after acquiring an additional 1,161,674 shares during the last quarter. Finally, Wellington Management Group LLP grew its position in shares of Zoetis by 135.5% during the third quarter. Wellington Management Group LLP now owns 4,705,256 shares of the company’s stock worth $913,476,000 after acquiring an additional 2,706,908 shares during the last quarter. Institutional investors own 90.73% of the company’s stock.
A number of equities analysts have recently issued reports on ZTS shares. Citigroup lowered their target price on shares of Zoetis from $232.00 to $208.00 and set a “neutral” rating on the stock in a research report on Wednesday, March 9th. StockNews.com downgraded Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 26th. Finally, The Goldman Sachs Group decreased their price target on Zoetis from $237.00 to $208.00 and set a “buy” rating for the company in a report on Thursday. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus target price of $231.88.
Zoetis stock traded up $3.93 during midday trading on Friday, reaching $162.56. The company’s stock had a trading volume of 2,395,200 shares, compared to its average volume of 2,505,326. Zoetis Inc. has a fifty-two week low of $156.67 and a fifty-two week high of $249.27. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.58 and a current ratio of 2.25. The stock’s 50 day simple moving average is $182.03 and its 200 day simple moving average is $201.77. The firm has a market capitalization of $76.51 billion, a PE ratio of 37.28, a P/E/G ratio of 2.67 and a beta of 0.77.
Zoetis (NYSE:ZTS – Get Rating) last released its earnings results on Thursday, May 5th. The company reported $1.32 EPS for the quarter, beating analysts’ consensus estimates of $1.23 by $0.09. Zoetis had a return on equity of 49.62% and a net margin of 26.27%. The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $1.98 billion. During the same quarter last year, the company earned $1.26 earnings per share. Zoetis’s quarterly revenue was up 6.9% compared to the same quarter last year. Equities analysts predict that Zoetis Inc. will post 5.06 earnings per share for the current year.
Zoetis Profile (Get Rating)
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
- Get a free copy of the StockNews.com research report on Zoetis (ZTS)
- MarketBeat: Week in Review 5/16 – 5/20
- 3 Retailers That Defied First Quarter Headwinds
- Rapid7: Could Be Profitable in FY 2022 Despite Bear Market
- Will John Deere’s Earnings Help to Calm the Markets?
- Lowe’s Companies Has Not Bottomed
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.